Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MLN9708 (Ixazomib Citrate) 抑制 20S 蛋白酶体的糜蛋白酶样蛋白水解 (β5) 位点 (Ki50=0.93 nM, IC50=3.4 nM/)。 MLN9708 的生物活性形式是水溶液或血浆中的 MLN2238。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 279 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 578 | 现货 | ||
25 mg | ¥ 919 | 现货 | ||
50 mg | ¥ 1,230 | 现货 | ||
100 mg | ¥ 1,980 | 现货 | ||
200 mg | ¥ 2,970 | 现货 | ||
500 mg | ¥ 4,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 472 | 现货 |
产品描述 | MLN2238 suppresses the chymotrypsin-like proteolytic (β5) site of the 20S proteasome(Ki50=0.93 nM, IC50=3.4 nM/). The biologically active form of MLN9708 (Ixazomib Citrate) is MLN2238 in aqueous solutions or plasma. |
靶点活性 | 20S proteasome:0.93 nM(Ki), 20S proteasome:3.4 nM |
体外活性 | 在多种实体瘤和血液移植瘤中,MLN9708有抗癌活性. |
体内活性 | MLN9708与水溶液和血浆接触后, MLN9708快速水解为具有生物活性的MLN2238。MLN2238抑制20S蛋白酶体的糜蛋白酶类水解位点(IC50=3.4 nM,Ki=0.93 nM)。MLN2238也抑制20S蛋白酶体的caspase类水解的位点(IC50=31 nM)和胰蛋白酶类水解的位点(IC50=3.5 μM)。 |
激酶实验 | Kinase assay: Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument. |
细胞实验 | Calu-6 cells are cultured in MEM containing 10% FBS and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. For IC50 determinations, cells are treated with varying concentrations of Bortezomib or MLN2238 in DMSO (0.5% final, v/v) for 1 hour at 37 °C. For reversibility experiments, cells are treated with either 1 μM Bortezomib or MLN2238 for 30 minutes at 37 °C and then washed thrice in medium to remove the Bortezomib or MLN2238. Cells are incubated for an additional 4 hours at 37 °C, after which the medium is removed and replaced with fresh medium. (Only for Reference) |
别名 | Ixazomib Citrate |
分子量 | 517.12 |
分子式 | C20H23BCl2N2O9 |
CAS No. | 1201902-80-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (179.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9338 mL | 9.6689 mL | 19.3379 mL | 48.3447 mL |
5 mM | 0.3868 mL | 1.9338 mL | 3.8676 mL | 9.6689 mL | |
10 mM | 0.1934 mL | 0.9669 mL | 1.9338 mL | 4.8345 mL | |
20 mM | 0.0967 mL | 0.4834 mL | 0.9669 mL | 2.4172 mL | |
50 mM | 0.0387 mL | 0.1934 mL | 0.3868 mL | 0.9669 mL | |
100 mM | 0.0193 mL | 0.0967 mL | 0.1934 mL | 0.4834 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MLN9708 1201902-80-8 Proteases/Proteasome Ubiquitination Proteasome MLN 9708 MLN-9708 Ixazomib Citrate Inhibitor inhibitor inhibit